15 news items
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
TAK
18 Jun 24
Takeda's Commitment to Continued Research on the Role of Immunoglobulin (IG) Therapy for Patients with Rare Neuroimmunological Disorders
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
ADVANCE Clinical Program Reflects Takeda's Commitment
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
as this study is an ongoing example of our steadfast commitment to working with leading data science companies to drive innovation and assist patients
nz1tw2dqd1 ievhslx3xmz302dks3gxfl6bhfppuqqgy67u
TAK
3 Jun 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries
7vao2h5v1 hg0vep4tgj8nonj4cgsl27lg1krc4
PFE
TAK
1 Jun 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions
o4ok5t0ukqt6mw2f0qyfq0a66gal iy9sffh7n1f8fw4afp
TAK
31 May 24
-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
5pr48c5qk0q
TAK
16 May 24
in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our
fasqclplm0f36oehetknilo28i s8h7yw3p2y7t
ACIU
TAK
13 May 24
development and be responsible for all global regulatory activities as well as worldwide commercialization. "At Takeda, we are committed
xg4w3eh0a55s232 k8mye
ACIU
TAK
13 May 24
as well as worldwide commercialization.
"At Takeda, we are committed to tackling some of society's most
axw2jemk2ih5nug3v4qu8xqxn30gpt3dfv2j4yqwx0vyn
TAK
9 May 24
Committed to 100-250 Basis Points Core Operating
biszr090d
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
ogcogck0
TAK
22 Apr 24
biopharmaceutical company headquartered in Japan, we are guided by our commitment
anmni4ki
TAK
18 Apr 24
Business Unit, Takeda. "Our development of a subcutaneous option demonstrates Takeda's commitment to meeting the very real needs of those living
- Prev
- 1
- Next